CymaBay Therapeutics (CBAY) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from a buy rating to a strong-buy rating in a research note published on Thursday, ValuEngine reports.

A number of other analysts also recently issued reports on the stock. Piper Jaffray Companies set a $30.00 price objective on shares of CymaBay Therapeutics and gave the stock a buy rating in a report on Friday, March 1st. Cantor Fitzgerald reaffirmed a buy rating and set a $20.00 price objective on shares of CymaBay Therapeutics in a report on Friday, February 1st. Roth Capital reaffirmed a buy rating on shares of CymaBay Therapeutics in a report on Tuesday, February 19th. Oppenheimer set a $18.00 price objective on shares of CymaBay Therapeutics and gave the stock a buy rating in a report on Friday, February 15th. Finally, BidaskClub raised shares of CymaBay Therapeutics from a hold rating to a buy rating in a report on Wednesday, February 27th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $19.38.

NASDAQ CBAY opened at $13.02 on Thursday. CymaBay Therapeutics has a 52-week low of $6.31 and a 52-week high of $15.00.

In other news, Director Carl Goldfischer sold 11,675 shares of CymaBay Therapeutics stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $9.02, for a total transaction of $105,308.50. Following the completion of the sale, the director now directly owns 2,335 shares of the company’s stock, valued at approximately $21,061.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.50% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CBAY. Great Point Partners LLC bought a new stake in CymaBay Therapeutics in the fourth quarter worth $11,164,000. BlackRock Inc. lifted its stake in CymaBay Therapeutics by 16.3% in the fourth quarter. BlackRock Inc. now owns 5,161,581 shares of the biopharmaceutical company’s stock worth $40,622,000 after purchasing an additional 722,753 shares during the last quarter. Foresite Capital Management IV LLC lifted its stake in CymaBay Therapeutics by 30.0% in the fourth quarter. Foresite Capital Management IV LLC now owns 2,631,258 shares of the biopharmaceutical company’s stock worth $20,708,000 after purchasing an additional 607,889 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in CymaBay Therapeutics by 107.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 716,974 shares of the biopharmaceutical company’s stock worth $5,643,000 after purchasing an additional 370,985 shares during the last quarter. Finally, Fosun International Ltd lifted its stake in CymaBay Therapeutics by 70.8% in the fourth quarter. Fosun International Ltd now owns 792,096 shares of the biopharmaceutical company’s stock worth $6,199,000 after purchasing an additional 328,289 shares during the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Recommended Story: What is Blockchain?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.